

Innovation all for the patients



CHUGAI PHARMACEUTICAL CO., LTD.



Roche Group



Chugai Pharmaceutical Co., Ltd.  
Maruishi Pharmaceutical Co., Ltd.

## Transfer and Future Marketing of Physiological Intestinal Function Improving and Hyperammonemia Drug "MONILAC<sup>®</sup> Syrup 65%" in Japan

TOKYO, July 22, 2024 -- [Chugai Pharmaceutical Co., Ltd.](#) [Head Office: Tokyo, President and CEO: Osamu Okuda] (hereafter, Chugai) and Maruishi Pharmaceutical Co., Ltd. [Head Office: Osaka, President and Representative Director: Katsuhito Inoue] (hereafter, Maruishi) announced that Chugai will transfer to Maruishi, the business in Japan concerning the physiological intestinal function improving and hyperammonemia drug "MONILAC<sup>®</sup> Syrup 65%" (hereafter, MONILAC) for which Chugai holds the manufacturing and marketing authorization in Japan.

Chugai has been marketing MONILAC and providing information in Japan since 1975. In consideration of the maturity of its product lifecycle, Chugai has been considering its future domestic marketing. As a result of discussions between Chugai and Maruishi, it was agreed that Chugai would transfer all assets relating to MONILAC in Japan, including manufacturing and marketing authorization and intellectual property rights such as trademarks, to Maruishi, and Maruishi would thereafter be responsible for sales of MONILAC. Maruishi, which has strengths in the basic drug field, will strive to maximize the value of MONILAC through synergy with its existing products.

Maruishi and Chugai are proceeding with the necessary administrative and legal procedures for the completion of the transaction. The sales transfer process is scheduled to complete by the end of February 2025, and we will inform relevant stakeholders once the sales transfer date has been decided.

Maruishi and Chugai will cooperate to ensure a stable supply and achieve a smooth transfer of the marketing authorization regarding MONILAC.

### **Chugai Pharmaceutical Co., Ltd.**

Chugai Pharmaceutical Co., Ltd., headquartered in Tokyo, is a research-based pharmaceutical company with world-class drug discovery capabilities, including proprietary antibody engineering technologies. Chugai is committed to creating innovative pharmaceutical products that may satisfy unmet medical needs. Chugai is listed on the Prime Market of the Tokyo Stock Exchange. While maintaining autonomy and management independence, Chugai is an important member of the Roche Group. Additional information is available at <https://www.chugai-pharm.co.jp/english/>

### **Maruishi Pharmaceutical Co., Ltd.**

Maruishi Pharmaceutical Co., Ltd. was founded in 1888 as a manufacturer of Japanese Pharmacopoeia medicines (basic drugs). Utilizing the technology, knowledge, and know-how it has cultivated over its 130-year history, Maruishi is contributing to healthcare by broadly researching, developing, and delivering drugs with the ultimate goal of improving patients' quality of life.

In recent years, Maruishi has been expanding into acute and emergency medical care and supportive medical care (cancer supportive care), building on our business foundations in the areas of perioperative medical care, infection control, and basic drugs.

Additional information is available at <https://www.maruishi-pharm.co.jp/english/>

### **Contact:**

#### **For Media**

Chugai Pharmaceutical Co., Ltd.

Media Relations Group, Corporate Communications Dept.

Tel: +81-3-3273-0881

E-mail: [pr@chugai-pharm.co.jp](mailto:pr@chugai-pharm.co.jp)

#### **For Investors**

Chugai Pharmaceutical Co., Ltd.

Investor Relations Group, Corporate Communications Dept.

Tel: +81-3-3273-0554

E-mail: [ir@chugai-pharm.co.jp](mailto:ir@chugai-pharm.co.jp)